Studies in mice have shown that conjugated linoleic acid (CLA) 2 lowers the proportion and amount of body fat (1-6) and that this effect is mediated by an enhanced energy expenditure (5-7). The body fat-lowering effect of CLA has also been reported in humans (8 -12), but it seems to be less prominent than in mice. The dose administered or the length of the feeding period may partly explain this difference in magnitude of the effect between mice and humans, but differences in metabolic rate may play a major role.
Studies in mice have shown that conjugated linoleic acid (CLA) 2 lowers the proportion and amount of body fat (1) (2) (3) (4) (5) (6) and that this effect is mediated by an enhanced energy expenditure (5-7). The body fat-lowering effect of CLA has also been reported in humans (8 -12) , but it seems to be less prominent than in mice. The dose administered or the length of the feeding period may partly explain this difference in magnitude of the effect between mice and humans, but differences in metabolic rate may play a major role.
The relationship between basal metabolic rate or energy expenditure and body weight in different size mammals is described by the function Y ϭ aX 0.75 , where Y is basal metabolic rate (kJ/d), X is body weight (kg) and a is basal metabolic rate per kg 0.75 per day, which is ϳ300 kJ/ (kg 0.75 ⅐ d) (13) (14) (15) . Thus, the basal metabolic rate in different size species is proportional to the body weight raised to the 0.75 power, the so called metabolic weight. If one assumes that the basal metabolic rate comprises ϳ75% of the total metabolic rate, then the total metabolic rate can be described by the function Y ϭ 400 X 0.75 . From this relationship, it follows that the total metabolic rate of a 70-kg human is 400 ϫ 70 0.75 ϭ 9680 kJ or 138 kJ per kg body weight. Similarly, the total metabolic rate of a 30 g mouse is 400 ϫ 0.030 0.75 ϭ 29 kJ or 961 kJ per kg body weight. A relative increase of 10% in energy expenditure per kg metabolic weight will also result in a 10% increase in the energy expenditure per kg body weight but the absolute increase in energy expenditure expressed in kJ per kg body weight will be greater in mice than in humans. Consequently, the reduction in body fat will also be greater in mice than in humans when a particular dose of CLA expressed in mg CLA per 1000 kJ energy intake or in mg CLA per kg metabolic weight [1 mg CLA per 1000 kJ energy intake ϭ (400/1000) ϭ 0.4 mg CLA per kg metabolic weight] will result in a similar relative increase in energy expenditure in both mice and humans. For example, an increase of 10% in energy expenditure and no change in energy intake will theoretically result in mice during a period of 30 d in a reduction of 0.10 (energy expenditure increase) ϫ 961 (energy expenditure in kJ per kg body weight) ϫ 30 (d) ϭ 2883 kJ energy per kg body weight, which is equivalent to 2883/39.8 ϭ 72.4 g of fat per kg body weight [the gross energy of body fat is 39.8 kJ per g (16)]. Similarly, it can be calculated that this 10% increase in energy expenditure will result in humans in a reduction of 414 kJ of energy per kg body weight, which is equivalent to 10.4 g of fat per kg body weight. Thus, theoretical calculations indicate that the reduction in body fat will be about seven times higher in mice than in humans because of the seven times higher metabolic rate per kg body weight. These calculations are based on the assumption that the increase in energy expenditure is exclusively at the expense of body fat, which is not always true (see footnote 2 of Table 1 ).
The theoretical calculations are in line with the experimental data from various studies in mice and humans. The normalized results indicate that the body fat-lowering effect of CLA is considerably lower in humans than in mice (Table 1 ). There are, however, large variations in the normalized results among the various studies in both mice and humans. Nevertheless, the normalized body fat-lowering effect of CLA is on average approximately seven times higher in mice than in humans, similar to what the theoretical calculations would predict. The results in Table 1 also seem to support the above assumption that a particular dose of CLA will result in a similar relative increase in energy expenditure in both mice and humans. However, it is not clear whether this might also be true for other species.
Thus, differences in metabolic rate may play a major role in explaining the differences between mice and humans in the body fat-lowering effect of CLA. The effects of CLA on energy metabolism observed in mice should be cautiously interpreted and extrapolation to humans should be done carefully. In contrast, the high metabolic rate of the mouse compared with humans may make the mouse an excellent model to study the effects of various dietary fats and other components on energy metabolism. 
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